In diffuse large B‐cell lymphoma (DLBCL) and multiple myeloma (MM), proteins such as CD79 and MyD88 have been found to activate NF‐κB through gain‐of‐function mutations. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.